[The use of holoxan (iphosphamide) in malignant tumors].
A clinical trial of holoxan in combination with a urological protector--uromitexan--was carried out. Response was observed in 26.3% of patients with lung cancer. The drug was effective in cases of soft tissue sarcoma and Ewing's sarcoma.